NCX4016: a novel antithrombotic agent

被引：11

作者：

Gresele, P ^{[1
]}

Momi, S ^{[1
]}

Mezzasoma, AM ^{[1
]}

机构：

[1] Univ Perugia, Dept Internal Med, Div Internal & Cardiovasc Med, I-06126 Perugia, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2003年 / 35卷

关键词：

antithrombotic agents; aspirin; nitric oxide; nitroaspirin;

D O I：

10.1016/S1590-8658(03)00048-3

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents. Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential. Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation-all activities not exerted by aspirin. In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive. Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：S20 / S26

页数：7

共 62 条

[1]

ARONOW HD, 2002, PLATELETS THROMBOTIC, P1013

[2]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[3]

BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185

[4] Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice [J].

Burleigh, ME ;

Babaev, VR ;

Oates, JA ;

Harris, RC ;

Gautam, S ;

Riendeau, D ;

Marnett, LJ ;

Morrow, JD ;

Fazio, S ;

Linton, MF .

CIRCULATION, 2002, 105 (15) :1816-1823

[5] Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].

Cannon, CP ;

Weintraub, WS ;

Demopoulos, LA ;

Vicari, R ;

Frey, MJ ;

Lakkis, N ;

Neumann, FJ ;

Robertson, DH ;

DeLucca, PT ;

DiBattiste, PM ;

Gibson, CM ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887

[6] ELECTRONIC AGGREGOMETER - NOVEL DEVICE FOR ASSESSING PLATELET BEHAVIOR IN BLOOD [J].

CARDINAL, DC ;

FLOWER, RJ .

JOURNAL OF PHARMACOLOGICAL METHODS, 1980, 3 (02) :135-158

[7]

Coller BS, 2001, THROMB HAEMOSTASIS, V86, P427

[8] PHARMACOLOGY OF PLATELET INHIBITION IN HUMANS - IMPLICATIONS OF THE SALICYLATE-ASPIRIN INTERACTION [J].

DEGAETANO, G ;

CERLETTI, C ;

DEJANA, E ;

LATINI, R .

CIRCULATION, 1985, 72 (06) :1185-1193

[9] NO-aspirins: a class of new antiinflammatory and antithrombotic agents [J].

del Soldato, P ;

Sorrentino, R ;

Pinto, A .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) :319-323

[10] Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature [J].

Emerson, M ;

Momi, S ;

Paul, W ;

Alberti, PF ;

Page, C ;

Gresele, P .

THROMBOSIS AND HAEMOSTASIS, 1999, 81 (06) :961-966

← 1 2 3 4 5 6 7 →